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We conducted a retrospective study of Salmonella New-
port infections among Wisconsin residents during 2003–
2005. Multidrug resistance prevalence was substantially 
greater in Wisconsin than elsewhere in the United States. 
Persons with multidrug-resistant infections were more likely 
than persons with susceptible infections to report exposure 
to cattle, farms, and unpasteurized milk.
D
uring the past decade, multidrug-resistant (MDR) 
Salmonella enterica serotype Newport strains in the 
United States have increased substantially (1). The preva-
lence of the most common MDR S. Newport phenotype, 
Newport-MDRAmpC, increased from 1% of human S. 
Newport isolates tested in 1998 to 21% of isolates tested 
in 2003 (2). Newport-MDRAmpC is resistant to at least 
chloramphenicol, streptomycin, sulfamethoxazole/sulﬁ  -
soxazole, tetracycline, amoxicillin-clavulanic acid, ampi-
cillin, cefoxitin, ceftiofur, and cephalothin. This phenotype 
exhibits decreased susceptibility to ceftriaxone (2), a criti-
cally important antimicrobial agent for treating invasive 
salmonellosis in children (3).
Studies suggest that dairy cattle are a major US reser-
voir for MDR S. Newport (4–6). However, data document-
ing the prevalence of MDR S. Newport among infected 
human case-patients in dairy-intensive states are limited. 
To assess the prevalence of resistance among S. Newport 
isolates in Wisconsin, which in 2002 had the greatest den-
sity of milk cows in the United States (7), we evaluated 
antimicrobial susceptibility data from S. Newport infec-
tions among Wisconsin case-patients during 2003–2005. 
We also compared information on potential exposures for 
case-patients with Newport-MDRAmpC and susceptible 
infections.
The Study
Surveillance data were electronically compiled for lab-
oratory-conﬁ  rmed S. Newport infections among Wisconsin 
residents with illness onsets from January 1, 2003, through 
December 31, 2005. Providers and local health depart-
ments reported hospitalization status; travel history; and 
exposure to raw milk, cattle, horses, reptiles, and dead ani-
mals. The study population included case-patients whose 
isolates were tested for antimicrobial drug susceptibility at 
the Wisconsin State Laboratory of Hygiene. Identiﬁ  cation 
and susceptibility testing were conducted on isolates from 
stool, urine, and blood samples.
Serotype identiﬁ   cation was performed according to 
the Kauffmann-White scheme (8). Slide and tube agglu-
tination were used for identiﬁ  cation of O (somatic) and H 
(ﬂ  agellar) antigens, respectively. All isolates were tested 
for susceptibility to ampicillin, amoxicillin-clavulanic acid, 
cefoxitin, ceftriaxone, cephalothin, chloramphenicol, cip-
roﬂ  oxacin, gentamicin, kanamycin, nalidixic acid, strepto-
mycin, sulﬁ  soxazole, tetracycline, and trimethoprim-sul-
famethoxazole, by using the Kirby-Bauer disk diffusion 
method. Results were interpreted according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines (9). Anti-
microbial agents were categorized into CLSI antimicrobial 
subclasses, and each isolate was assigned to >1 categories 
according to its antimicrobial resistance phenotype and the 
number of subclasses to which it was resistant (National 
Antimicrobial Resistance Monitoring System for Enteric 
Bacteria [NARMS], pers. comm.; Table 1). Pansusceptible 
isolates were deﬁ  ned as isolates that had no detected antimi-
crobial drug resistance. Because isolates were not tested for 
ceftiofur resistance, our deﬁ  nition of Newport-MDRAmpC 
did not include resistance to this drug.
The prevalence of each type of resistance among S. 
Newport isolates from Wisconsin case-patients was com-
pared with that reported elsewhere in the United States, by 
using 2003 and preliminary 2004 NARMS data. Data were 
analyzed by using Epi Info 2002, version 3.3.2 (Centers 
for Disease Control and Prevention, Atlanta, GA, USA); 
to assess associations between antimicrobial resistance and 
reported exposures, odds ratios and Mantel-Haenszel and 
Fisher exact 2-tailed p values were calculated where ap-
propriate.
Serotyping and antimicrobial drug susceptibility test-
ing were conducted on S. Newport isolates from 268 case-
patients. Median age was 34 years (range <1–96 years); 
of 267  case-patients for whom sex was reported, 57% 
were female. Resistance patterns are provided in Table 1. 
Among the 5 (2%) quinolone-resistant isolates (2 resistant 
to nalidixic acid and ciproﬂ  oxacin, 2 resistant to nalidixic 
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acid only, and 1 resistant to ciproﬂ  oxacin only), 4 were 
ceftriaxone resistant and 1 was MDRAmpC resistant. The 
frequencies of antimicrobial drug resistance among Wis-
consin S. Newport isolates were substantially greater for all 
resistance subgroups than frequencies reported elsewhere 
in the United States during 2003 and 2004 (NARMS, pers. 
comm.; Table 1; Figure).
Of 194 case-patients for whom hospitalization status 
was reported, 46 (24%) had been hospitalized. Of case-pa-
tients with Newport-MDRAmpC and pansusceptible in-
fections, similar proportions were hospitalized (26% and 
24%, respectively) and had known hospitalization status 
(72% and 73%, respectively). Two case-patients died: an 
84-year-old woman and a 37-year-old man for whom sal-
monellosis was not considered the probable cause of death. 
The 2 associated isolates were pansusceptible.
Persons infected with Newport-MDRAmpC were sig-
niﬁ  cantly more likely than persons infected with pansus-
ceptible S. Newport to be male and to have had contact 
with cattle, to have drunk unpasteurized milk, and to live 
on or have visited a farm or petting zoo (Table 2). Reported 
exposure to reptiles was signiﬁ  cantly associated with pan-
susceptible infection (Table 2). No association was found 
between hospitalization and resistance (odds ratio [OR] 
1.09, p = 0.81).
Conclusions
We describe a substantially greater prevalence of 
MDRAmpC resistance among Wisconsin case-patients 
with S. Newport infections that occurred during 2003–2005, 
compared with data reported elsewhere in the United States 
(NARMS, personal communication, 2007). This ﬁ  nding is 
of particular concern because Newport-MDRAmpC ex-
hibits decreased susceptibility to ceftriaxone, a third-gen-
eration cephalosporin that is the treatment of choice for 
invasive salmonellosis in children (3). Additionally, be-
cause the blaCMY-2 gene that confers ceftriaxone resistance 
in Newport-MDRAmpC is located on a plasmid that was 
readily transferred between Escherichia coli in laboratory 
assays (10), propagation of Newport-MDRAmpC could in-
crease the spread of CMY-2 plasmids to other bacteria.
Patients with Newport-MDRAmpC infection were 
more likely than patients with pansusceptible infections to 
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Table 1. Antimicrobial drug resistance patterns of human Salmonella Newport isolates among case-patients* 
Frequency (%) 
Resistant to
Wisconsin (n = 268),
2003–2005
Rest of United States (n = 402),  
2003–2004
None detected  95 (35) 317 (79)
>1 CLSI subclass† 173 (65) 85 (21)
>2 CLSI subclasses 150 (56) 81 (20)
>3 CLSI subclasses 150 (56) 77 (19)
>4 CLSI subclasses 150 (56) 74 (18)
>5 CLSI subclasses 146 (55) 71 (18)
At least ACSSuT‡  139 (52) 69 (17)
At least ACSuTm§ 7 (3) 4 (1)
At least MDRAmpC¶  137 (51) 68 (17)
Quinolone and cephalosporin (third generation)# 5 (2)** 2 (0.5)
*Based on data from the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. 
†CLSI, Clinical and Laboratory Standards Institute. Subclasses included aminoglycosides (kanamycin, gentamicin, streptomycin), aminopenicillins 
(ampicillin), β-lactamase inhibitor combinations (amoxicillin-clavulanic acid), first-generation cephalosporins (cephalothin), third-generation cephalosporins 
(ceftriaxone), cephamycins (cefoxitin), folate pathway inhibitors (trimethoprim-sulfamethoxazole), phenicols (chloramphenicol), quinolones (nalidixic acid, 
ciprofloxacin), sulfonamides (sulfisoxazole), and tetracyclines (tetracycline). 
‡ACSSuT, ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline. 
§ACSuTm, ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole. 
¶At least drugs to which MDRAmpC is resistant: chloramphenicol, streptomycin, trimethoprim-sulfamethoxazole, sulfisoxazole, tetracycline, amoxicillin-
clavulanic acid, ampicillin, cefoxitin, cephalothin, and ceftriaxone. Note: the Wisconsin State Laboratory of Hygiene does not routinely test Salmonella
isolates for resistance to ceftiofur, a third-generation cephalosporin that is related to ceftriaxone. 
#Resistant to ciprofloxacin and/or nalidixic acid, and ceftriaxone. 
**1 isolate in this category was also MDRAmpC. 
Figure. Antimicrobial drug resistance patterns of human Salmonella 
Newport isolates from Wisconsin (2003–2005) and elsewhere in 
the United States (2003–2004), based on data provided by the 
National Antimicrobial Resistance Monitoring System for Enteric 
Bacteria (NARMS). 2005 NARMS data were not available at the 
time of publication of this report. Antimicrobial subclasses are as 
deﬁ  ned by the Clinical and Laboratory Standards Institute (9). SC, 
subclass; M*, MDRAmpC.Human Multidrug-Resistant Salmonella Newport
report contact with cattle, farms, and unpasteurized milk. 
These exposures are likely to be more common among pa-
tients with Newport-MDRAmpC infection than among the 
general Wisconsin population, which suggests that dairy 
cattle are an important reservoir for Newport-MDRAmpC. 
Increased prevalence of Newport-MDRAmpC in Wiscon-
sin may be due to selective pressure from the use of anti-
microbial drugs on dairy farms (1), particularly ceftiofur, 
an extended-generation cephalosporin closely related to 
ceftriaxone (which is commonly used in cattle) (11). Clon-
ally and independently acquired CMY-2–associated ceftio-
fur resistance has been identiﬁ  ed among Salmonella strains 
isolated from dairy farms (12).
Few published data are available on the prevalence of 
Newport-MDRAmpC in other dairy-intensive states. Min-
nesota, which in 2002 had the eighth-greatest density of 
milk cows in the United States (7), reported a signiﬁ  cant 
increase in MDR S. Newport among human isolates dur-
ing 1996–2003, including an increase in the percentage of 
isolates with decreased susceptibility to ceftriaxone (13). 
However, NARMS reported a similar increase in Newport-
MDRAmpC prevalence nationally during 1998–2003 (2). 
Analyses of unpublished data provided by the Minnesota 
Department of Health indicated that 22% of 147 human 
isolates tested had antimicrobial drug resistance proﬁ  les 
consistent with the Newport-MDRAmpC phenotype dur-
ing 2003–2005; this prevalence is much lower than that 
among Wisconsin case-patients who were ill during the 
same period. Although differences in enteric disease sur-
veillance could partially explain this discrepancy, New-
port-MDRAmpC’s emergence in dairy cattle is likely to be 
associated with several factors.
Our ﬁ  ndings underscore the need for intensive New-
port-MDRAmpC surveillance in major dairy states. Efforts 
to promote the conservative and appropriate use of ceftio-
fur and other antimicrobial drugs in dairy cattle are indicat-
ed; they should be complemented by strategies to discour-
age transmission of MDR Salmonella among cattle, such 
as separating ill from parturient animals and disinfecting 
environmental niches (14). Furthermore, providers should 
be discouraged from prescribing antimicrobial drugs to pa-
tients with low-risk Salmonella infections (15), and public 
health messages should emphasize the importance of pas-
teurizing milk and cooking meat appropriately.
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